Pfizer’s Besponsa First Prescribed in China for Leukemia Treatment
US major Pfizer (NYSE: PFE) has announced the first prescriptions for its leukemia therapy Besponsa...
Kelun Pharmaceutical Receives USD 30 Million from MSD for Licensing Deal
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced receiving USD 30 million from...
ImmuneOnco Biopharmaceuticals Files for HKSE IPO with Comprehensive Tumor Immunotherapy Pipeline
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has submitted an initial public offering (IPO) filing to the...
Clover Biopharmaceuticals’ SCB-2019 COVID-19 Vaccine Shows Strong Immune Response in Third Shot Study
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has published clinical data for its COVID-19 vaccine candidate...
Harbour BioMed Receives FDA Approval for HBM7008 Clinical Trials
China-based Harbour BioMed (HKG: 2142) has announced receiving clinical trial approval from the US FDA...
Sinovac Biotech’s CoronaVac Receives Conditional Registration from South African Regulator
China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced that the South African Health Products Regulatory...
Joysbio Develops Rapid Test for SARS-CoV-2 Omicron Subvariants BA.4 and BA.5
China-based Joysbio (Tianjin) Biotechnology Co., Ltd. has developed a rapid test to diagnose the latest...
Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma
China-based Antengene Corporation Ltd (HKG: 6996) has announced a clinical trial collaboration with BeiGene Inc....
7th National VBP Round Venue Moved to Nanjing from Shanghai
In a departure from previous practice, the 7th national volume-based procurement (VBP) round will not...
Sino Biopharmaceutical’s TQ-B3101 Accepted by NMPA for ROS1+ NSCLC Treatment
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the National Medical Products Administration (NMPA)...
Ascletis Pharma Presents ASC22 Phase IIb Results for Chronic Hepatitis B at ILC 2022
China-based Ascletis Pharma Inc. (HKG: 1672) presented the latest results of a Phase IIb clinical...
Cosunter Pharma’s HBV Surface Antigen Inhibitor GST-HG121 Approved for Phase I Trial
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced receiving approval from the ethics...
Sanyou Biopharmaceuticals and Dragon Sail Form Strategic Partnership for Global Biopharma Services
China-based Sanyou Biopharmaceuticals Co., Ltd has entered into a long-term strategic partnership with compatriot firm...
NMPA Approves Senscure’s Cryoablation Catheter and Kangduo’s Laparoscopic Surgery System
The National Medical Products Administration (NMPA) has approved two innovative medical devices in China: Ningbo...
Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline
Hangzhou-based cell therapy firm Westlake Therapeutics, founded in 2019, has successfully raised over RMB 100...
PhenoVision Bio Secures Angel Funding for Spatial Multi-Omics Technology Platform
Beijing-based PhenoVision Biotech, a one-stop spatial multi-omics solution provider, has reportedly secured “tens of millions”...
GSK Launches Nucala in China for Eosinophilic Granulomatosis with Polyangiitis
UK pharmaceutical giant GlaxoSmithKline (GSK, LON: GSK, NYSE: GSK) has announced the official market launch...
Genor Biopharma and Abogen Biosciences Collaborate on Cancer mRNA Therapies
China’s Genor Biopharma Co., Ltd (HKG: 6998) has entered into a co-development agreement with compatriot...
Kexing Pharmaceutical’s Oral COVID-19 Drug SHEN26 Accepted for Clinical Trial Review
China-based Kexing Pharmaceutical (SHA: 688136) announced that a clinical trial application for SHEN26, an oral...
Sunshine Guojian Pharmaceutical Signs Licensing Deal for Cipterbin ADC Development
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has...